Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 3/20 | 0.62 |
| ▸ | TP53 | P04637 | 5/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | NLRP3 | Q96P20 | 5/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.47 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25633990 | 0.89 | THRB (0.77) | THRBTP53NPC1MAPTNLRP3 | |
| SCHEMBL23975810 | 0.88 | KMT2A (0.59) | THRBTP53NPC1MAPTNLRP3 | |
| SCHEMBL25272160 | 0.88 | KMT2A (0.59) | THRBTP53NPC1MAPTNLRP3 | |
| SCHEMBL25633409 | 0.86 | NLRP3 (0.72) | THRBTP53NPC1MAPTNLRP3 | |
| SCHEMBL25633396 | 0.86 | NLRP3 (0.73) | THRBTP53NLRP3 | |
| SCHEMBL25634301 | 0.82 | TP53 (0.70) | THRBTP53NPC1MAPTNLRP3 | |
| SCHEMBL25633342 | 0.79 | NPC1 (0.72) | THRBTP53NPC1MAPTNLRP3 | |
| SCHEMBL23950509 | 0.79 | NLRP3 (0.53) | THRBTP53MAPTNLRP3KMT2A | |
| SCHEMBL23975557 | 0.77 | THRB (1.00) | THRBTP53NPC1KMT2A | |
| SCHEMBL30073575 | 0.77 | THRB (1.00) | THRBTP53NPC1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183249-A1 | NEW TRIAZINOINDOLE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-15 | — | — | US | disclosed |
| US-20230183249-A1 | NEW TRIAZINOINDOLE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183249-A1 | NEW TRIAZINOINDOLE COMPOUNDS | NLRP3, NLRP1, PYCARD | THRB 277/4885TP53 1754/4885NPC1 364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.